

Ophthotech Corporation to Present at Chardan's 2nd Annual Genetic Medicines Conference

October 3, 2018

NEW YORK--(BUSINESS WIRE)--Oct. 3, 2018-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Keith Westby, Chief Operating Officer, will present an overview of the Company at Chardan's 2nd Annual Genetic Medicines Conference, on Tuesday, October 9, 2018 at 8:30 a.m. Eastern Time.

Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations section on the Ophthotech website at <u>www.ophthotech.com</u>. An archived replay of the webcast will be available on the Company's website immediately following the conference.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapies for age-related and orphan diseases of the eye. For more information, please visit <u>www.ophthotech.com</u>.

Forward-looking Statements

Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005150/en/

Source: Ophthotech Corporation

Investors: Ophthotech Corporation Kathy Galante, 212-845-8231 Vice President, Investor Relations and Corporate Communications kathy.galante@ophthotech.com or Media: SmithSolve Alex Van Rees, 973-442-1555 ext. 111 alex.vanrees@smithsolve.com